ITUS Corporation (NASDAQ:ITUS), today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has evidenced compliance with all requirements for continued listing on The Nasdaq Capital Market.  On August 24, 2016, the company was notified by NASDAQ that it no longer met the minimum continued listing requirements, and the August 24 matter is now closed.

ITUS is developing CchekÔ, a proprietary early cancer detection technology which measures a patient’s immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream.

ITUS Corporation

ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology.  The Company is developing a platform called CchekÔ, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body’s immunological response to the presence of a malignancy.  Additional information is available at www.ITUScorp.com.